Drugs / GX-E2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02291991 | Nov 2014 → Jan 2015 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02044653 | Apr 2014 → Apr 2017 | anemia, chronic kidney disease | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291991 ↗ |
| Route | Subcutaneous | “GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg” NCT02044653 ↗ |